FcγRIIb captures its ligand and targets it to lysosomal degradation following endocytosis. Here authors design bispecific-antibody-like molecules they call FcγRIIb-targeting chimeras or FcRTACs, to capture antigens with one arm and degrade them via an FcγRIIb-binding second arm to promote the clearance of pathological protein aggregates.
- Mingjuan Du
- Na Li
- Hongkai Zhang
